Director/PDMR Shareholding

Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4

On 1 August 2014, Leif Johansson, a Director of the Company notified us that, on 1 August 2014, he sold and purchased AstraZeneca PLC Ordinary Shares of $0.25 each.

As a result of these transactions, Mr Johansson has increased his total interest by 6,000 AstraZeneca shares.

Mr Johansson holds some of his AstraZeneca shares in pension arrangements in Sweden. One part of these arrangements has closed, resulting in the sale of shares. In order to maintain his interest in AstraZeneca shares, Mr Johansson has reinvested the sale proceeds.

Details of the sale and purchase are as follows:

1,000 shares sold at a price of SEK 503.00 per share.

1,000 shares purchased at a price of SEK 503.00 per share.

In addition, on 1 August 2014, Mr Johansson purchased a further 6,000 shares at a price of SEK 502.95 per share.

On 31 July 2014, certain other Directors of the Company notified us that, on 31 July 2014, they purchased AstraZeneca PLC Ordinary Shares of $0.25 each, as follows:

Name of Director Number of shares purchased Purchase price
Geneviève Berger 300 4324p
Shriti Vadera 3,500 4328p
John Varley 3,500 4370p

A C N Kemp
Company Secretary
1 August 2014

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links